Hofseth BioCare Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Jon Odegard
Chief executive officer
kr2.8m
Total compensation
CEO salary percentage | 58.6% |
CEO tenure | 1.8yrs |
CEO ownership | n/a |
Management average tenure | 3.3yrs |
Board average tenure | 2.4yrs |
Recent management updates
Recent updates
Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt
Apr 01We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt
Dec 22Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?
Apr 28Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt
Oct 16Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?
Feb 24How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?
Jan 28Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?
Dec 25Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain
Nov 20CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | kr3m | kr2m | -kr107m |
Sep 30 2023 | n/a | n/a | -kr93m |
Jun 30 2023 | n/a | n/a | -kr105m |
Mar 31 2023 | n/a | n/a | -kr140m |
Dec 31 2022 | n/a | n/a | -kr137m |
Sep 30 2022 | n/a | n/a | -kr136m |
Jun 30 2022 | n/a | n/a | -kr139m |
Mar 31 2022 | n/a | n/a | -kr135m |
Dec 31 2021 | n/a | n/a | -kr126m |
Sep 30 2021 | n/a | n/a | -kr120m |
Jun 30 2021 | n/a | n/a | -kr115m |
Mar 31 2021 | n/a | n/a | -kr111m |
Dec 31 2020 | kr2m | kr695k | -kr102m |
Sep 30 2020 | n/a | n/a | -kr104m |
Jun 30 2020 | n/a | n/a | -kr90m |
Mar 31 2020 | n/a | n/a | -kr86m |
Dec 31 2019 | kr2m | kr660k | -kr89m |
Sep 30 2019 | n/a | n/a | -kr79m |
Jun 30 2019 | n/a | n/a | -kr81m |
Mar 31 2019 | n/a | n/a | -kr83m |
Dec 31 2018 | kr2m | kr702k | -kr85m |
Sep 30 2018 | n/a | n/a | -kr74m |
Jun 30 2018 | n/a | n/a | -kr66m |
Mar 31 2018 | n/a | n/a | -kr66m |
Dec 31 2017 | kr2m | kr2m | -kr16m |
Compensation vs Market: Jon's total compensation ($USD255.95K) is about average for companies of similar size in the Norwegian market ($USD312.48K).
Compensation vs Earnings: Jon's compensation has increased whilst the company is unprofitable.
CEO
Jon Odegard
1.8yrs
Tenure
kr2,841,000
Compensation
Mr. Jon Olav Odegard had been Chief Financial Officer of Hofseth BioCare ASA since August 29, 2016 until 2022 and serves as its Chief Executive Officer since August 1, 2022 and was its Chief Executive Offi...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Executive Officer | 1.8yrs | kr2.84m | no data | |
CFO & COO | 1.2yrs | kr1.45m | 0.019% NOK 150.2k | |
Chief Scientific Officer | 14.3yrs | kr9.44m | 1.32% NOK 10.6m | |
Chief Commercial Officer | 3.3yrs | kr501.00k | no data | |
Chief Quality Officer | 3.3yrs | kr1.26m | no data | |
Head of Medical R&D and Director | no data | kr96.00k | 0.19% NOK 1.5m |
3.3yrs
Average Tenure
Experienced Management: HBC's management team is considered experienced (3.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Head of Medical R&D and Director | 2.3yrs | kr96.00k | 0.19% NOK 1.5m | |
Chair of the Board | 1.8yrs | kr96.00k | 17.59% NOK 141.1m | |
Independent Director | 2.4yrs | no data | no data | |
Independent Director | 9.3yrs | kr116.00k | 0.20% NOK 1.6m | |
Independent Director | 8.9yrs | kr116.00k | 0.051% NOK 406.0k |
2.4yrs
Average Tenure
49yo
Average Age
Experienced Board: HBC's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.